News
MHLW (Japan)approved Rinvoq to treat Ankylosing Spondylitis.- AbbVie
Japan’s Ministry of Health, Labor and Welfare (MHLW) approved label expansion for AbbVie’s JAK inhibitor Rinvoq (upadacitinib).
Rinvoq was approved for the additional indication of ankylosing spondylitis, with its use limited to cases that cannot be adequately treated with existing therapies. This is the drug’s fourth indication in Japan, after rheumatoid arthritis, psoriatic arthritis, and atopic dermatitis.
Condition: Ankylosing Spondylitis
Type: drug